What is Allelica?
Allelica is a leader in precision medicine, specializing in the integration of genetic insights into clinical workflows. The company's core offering revolves around polygenic risk scoring (PRS), a sophisticated method for stratifying disease risk among patients. Their Allelica Precision Server platform empowers healthcare providers with advanced tools to deliver personalized risk assessments, particularly for cardiovascular diseases. Furthermore, Allelica facilitates the development of genetic tests for the biotech and pharmaceutical sectors, ensuring adherence to stringent clinical standards, and actively engages with research institutions to refine genetic risk assessment accuracy across diverse populations.
How much funding has Allelica raised?
Allelica has raised a total of $1.8M across 1 funding round:
Angel/Seed
$1.8M
Angel/Seed (2021): $1.8M with participation from GeneCare Medical Genetics Center, Valor Ventures, and Pi Campus
Key Investors in Allelica
GeneCare Medical Genetics Center
GeneCare Medical Genetics Center is an entity likely focused on advancing genetic diagnostics and research, potentially providing strategic backing to companies like Allelica that enhance clinical genetics.
Valor Ventures
Valor Ventures is a venture capital firm that typically invests in innovative companies, likely specializing in early-stage or growth-stage technology and healthcare ventures.
Pi Campus
Pi Campus is an investment firm that supports startups, often with a focus on technology and innovation, indicating a strategic interest in Allelica's precision medicine platform.
What's next for Allelica?
With the recent major strategic investment, Allelica is poised to accelerate its development and deployment of precision medicine solutions. This capital infusion is expected to fuel further innovation in polygenic risk scoring, expand the platform's capabilities for disease risk stratification, and strengthen collaborations with research and industry partners. The company's focus on enterprise-level funding suggests a strategic push towards broader market penetration and the scaling of its genetic test development services, aiming to solidify its position as a key player in personalized healthcare.
See full Allelica company page
